Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 382-388

  Wang, Xiaokai ^a   Lai, Pinglin ^c   Zhang, Zhongmin ^a   Huang, Minjun ^a   Wang, Liang ^a   Yin, Min ^b   Jin, Dadi ^a   Zhou, Rongping ^b   Bai, Xiaochun ^a,c  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Mammalian target of rapamycin complex 2; Migration; MTOR kinase inhibitor; Osteosarcoma

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; CASPASE 7; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; RAPAMYCIN; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PURINE DERIVATIVE; RICTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WOUND HEALING; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; MULTIPROTEIN COMPLEXES; OSTEOSARCOMA; PURINES; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84903141093     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3182     Document Type: Article

References (32)

1. Biermann JS, Adkins D, Benjamin R, et al: Bone cancer. J Natl Compr Cancer Netw 5: 420-437, 2007.
2. Demetri GD, Baker LH, Benjamin RS, et al: Soft tissue sarcoma. J Natl Compr Cancer Netw 5: 364-399, 2007.
3. Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004. (Pubitemid 39014554)
4. Patel SR, Vadhan-Raj S, Burgess MA, et al: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21: 317-321, 1998. (Pubitemid 28280151)
5. Zoncu R, Efeyan A and Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2011.
6. Guertin DA and Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361, 2005. (Pubitemid 41080576)
7. Fasolo A and Sessa C: Targeting mTOR pathways in human malignancies. Curr Pharm Des 18: 2766-2777, 2012.
8. Benjamin D, Colombi M, Moroni C and Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10: 868-880, 2011.
9. Houghton PJ: Everolimus. Clin Cancer Res 16: 1368-1372, 2010.
10. Guertin DA and Sabatini DM: The pharmacology of mTOR inhibition. Sci Signal 2: pe24, 2009.
11. Feldman ME, Apsel B, Uotila A, et al: Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38, 2009.
12. Yu K, Shi C, Toral-Barza L, et al: Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70: 621-631, 2010.
13. Thoreen CC, Kang SA, Chang JW, et al: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J Biol Chem 284: 8023-8032, 2009.
14. Janes MR, Limon JJ, So L, et al: Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213, 2010.
15. Schenone S, Brullo C, Musumeci F, et al: ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 18: 2995-3014, 2011.
16. Shao H, Gao C, Tang H, et al: Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J Hepatol 56: 176-183, 2012.
17. Zhang YJ, Duan Y and Zheng XF: Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 16: 325-331, 2011.
18. Bai X, Ma D, Liu A, et al: Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318: 977-980, 2007. (Pubitemid 350098994)
19. Li H, Lin J, Wang X, et al: Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat 134: 1057-1066, 2012.
20. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
21. Li DM and Feng YM: Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat 128: 7-21, 2011.
22. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
23. Cohen SM and Lippard SJ: Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67: 93-130, 2001. (Pubitemid 33804642)
24. Thoreen CC and Sabatini DM: Rapamycin inhibits mTORC1, but not completely. Autophagy 5: 725-726, 2009.
25. Carew JS, Kelly KR and Nawrocki ST: Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6: 17-27, 2011.
26. Masri J, Bernath A, Martin J, et al: mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res 67: 11712-11720, 2007.
27. Guertin DA, Stevens DM, Saitoh M, et al: mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159, 2009.
28. Shorning BY, Griffiths D and Clarke AR: Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One 6: e16209, 2011.
29. Gulhati P, Bowen KA, Liu J, et al: mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71: 3246-3256, 2011.
30. Inoki K, Mori H, Wang J, et al: mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121: 2181-2196, 2011.
31. Proud CG: mTOR signalling in health and disease. Biochem Soc Trans 39: 431-436, 2011.
32. Sparks CA and Guertin DA: Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29: 3733-3744, 2010.